fasudil has been researched along with Disease Exacerbation in 19 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to explore the anti-tumor effects of Rho/ROCK inhibitor, fasudil, including the possible mechanisms involved in the suppression of the glioblastoma (GBM) cell line progression in vitro and in vivo." | 7.76 | Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. ( Deng, L; He, Q; Li, G; Li, R; Liu, Q; Zhang, J, 2010) |
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 5.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| " We show an example how DES-ncRNA can aid research on Alzheimer disease and suggest potential therapeutic role for Fasudil." | 3.85 | DES-ncRNA: A knowledgebase for exploring information about human micro and long noncoding RNAs based on literature-mining. ( Alam, T; Bajic, VB; Bajic, VP; Essack, M; Ma, L; Marchand, B; Radovanovic, A; Salhi, A; Schmeier, S; Zhang, Z, 2017) |
| " Fasudil can restrain EMT induced by PTH; this conclusion provides experimental data for the application of fasudil in the clinical prevention and treatment of renal fibrosis." | 3.85 | The influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone. ( Cui, T; Gao, Z; Li, Z; Zhang, H; Zhu, W, 2017) |
| " The aim of this study was to explore the anti-tumor effects of Rho/ROCK inhibitor, fasudil, including the possible mechanisms involved in the suppression of the glioblastoma (GBM) cell line progression in vitro and in vivo." | 3.76 | Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo. ( Deng, L; He, Q; Li, G; Li, R; Liu, Q; Zhang, J, 2010) |
| "Pancreatic cancer development and metastasis occur in complex settings, with reciprocal feedback from microenvironmental cues influencing both disease progression and drug response." | 1.46 | Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. ( Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A, 2017) |
| "Moreover, fasudil slowed disease progression, increased survival time and reduced motor neuron loss, in SOD1(G93A) mice." | 1.39 | Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. ( Hara, H; Kawasaki, K; Kimura, M; Nagahara, Y; Seto, M; Shimazawa, M; Takata, M; Tanaka, H; Tanaka, K; Tsuruma, K, 2013) |
| "Fasudil ameliorates disease progression in EAE, acting possibly through antiinflammatory pathway." | 1.38 | Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. ( Feng, L; Guo, MF; Hou, SW; Li, YH; Liu, CY; Liu, YT; Ma, CG; Meng, J; Xiao, BG; Xie, Y; Yu, JZ; Zhang, HF, 2012) |
| "Treatment with fasudil or gefitinib completely inhibited glomerular cell proliferation without changing the BP." | 1.37 | Comparison of ROCK and EGFR activation pathways in the progression of glomerular injuries in AngII-infused rats. ( Eguchi, S; Fujigaki, Y; Hishida, A; Suzuki, H; Yamamoto, T, 2011) |
| "Groups 2-4 (n=15 each) were subjected to cerebral aneurysm induction procedures plus 1% NaCl in the drinking water." | 1.36 | Fasudil, a Rho-kinase inhibitor, attenuates induction and progression of cerebral aneurysms: experimental study in rats using vascular corrosion casts. ( Eldawoody, H; Kimura, N; Nakayama, T; Saito, A; Shimizu, H; Takahashi, A; Tominaga, T, 2010) |
| "The fasudil-treated mice exhibited a significant reduction in ROCK activity, albuminuria, glomerular collagen IV accumulation, and urinary collagen IV excretion compared with untreated db/db mice." | 1.35 | Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. ( Danesh, FR; Kolavennu, V; Peng, H; Wang, Y; Zeng, L, 2008) |
| "Fasudil has been approved for the treatment of cerebral vasospasm and associated cerebral ischemic symptoms." | 1.33 | The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. ( Alicke, B; Biroc, SL; Dinter, H; Kamata, Y; Li, WW; Ohashi, Y; Okada, T; Pagila, R; Xuan, JA; Ying, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Vennin, C | 2 |
| Chin, VT | 1 |
| Warren, SC | 1 |
| Lucas, MC | 1 |
| Herrmann, D | 1 |
| Magenau, A | 1 |
| Melenec, P | 1 |
| Walters, SN | 1 |
| Del Monte-Nieto, G | 1 |
| Conway, JR | 1 |
| Nobis, M | 1 |
| Allam, AH | 1 |
| McCloy, RA | 1 |
| Currey, N | 1 |
| Pinese, M | 1 |
| Boulghourjian, A | 1 |
| Zaratzian, A | 1 |
| Adam, AA | 1 |
| Heu, C | 1 |
| Nagrial, AM | 1 |
| Chou, A | 1 |
| Steinmann, A | 1 |
| Drury, A | 1 |
| Froio, D | 1 |
| Giry-Laterriere, M | 1 |
| Harris, NL | 1 |
| Phan, T | 1 |
| Jain, R | 1 |
| Weninger, W | 1 |
| McGhee, EJ | 1 |
| Whan, R | 1 |
| Johns, AL | 1 |
| Samra, JS | 1 |
| Chantrill, L | 1 |
| Gill, AJ | 1 |
| Kohonen-Corish, M | 1 |
| Harvey, RP | 1 |
| Biankin, AV | 1 |
| Evans, TR | 1 |
| Anderson, KI | 1 |
| Grey, ST | 1 |
| Ormandy, CJ | 1 |
| Gallego-Ortega, D | 1 |
| Wang, Y | 2 |
| Samuel, MS | 1 |
| Sansom, OJ | 1 |
| Burgess, A | 1 |
| Cox, TR | 1 |
| Morton, JP | 1 |
| Pajic, M | 2 |
| Timpson, P | 2 |
| Salhi, A | 1 |
| Essack, M | 1 |
| Alam, T | 1 |
| Bajic, VP | 1 |
| Ma, L | 1 |
| Radovanovic, A | 1 |
| Marchand, B | 1 |
| Schmeier, S | 1 |
| Zhang, Z | 1 |
| Bajic, VB | 1 |
| Gao, Z | 1 |
| Zhu, W | 1 |
| Zhang, H | 1 |
| Li, Z | 1 |
| Cui, T | 1 |
| Hensel, N | 1 |
| Baskal, S | 1 |
| Walter, LM | 1 |
| Brinkmann, H | 1 |
| Gernert, M | 1 |
| Claus, P | 1 |
| Rath, N | 1 |
| Olson, MF | 1 |
| Rashid, J | 1 |
| Nahar, K | 1 |
| Raut, S | 1 |
| Keshavarz, A | 1 |
| Ahsan, F | 1 |
| Matoba, K | 1 |
| Kawanami, D | 1 |
| Okada, R | 1 |
| Tsukamoto, M | 1 |
| Kinoshita, J | 1 |
| Ito, T | 1 |
| Ishizawa, S | 1 |
| Kanazawa, Y | 1 |
| Yokota, T | 1 |
| Murai, N | 1 |
| Matsufuji, S | 1 |
| Takahashi-Fujigasaki, J | 1 |
| Utsunomiya, K | 1 |
| Takata, M | 1 |
| Tanaka, H | 1 |
| Kimura, M | 1 |
| Nagahara, Y | 1 |
| Tanaka, K | 1 |
| Kawasaki, K | 1 |
| Seto, M | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Hara, H | 1 |
| Grise, F | 1 |
| Bidaud, A | 1 |
| Moreau, V | 1 |
| Wu, DJ | 1 |
| Xu, JZ | 1 |
| Wu, YJ | 1 |
| Jean-Charles, L | 1 |
| Xiao, B | 1 |
| Gao, PJ | 1 |
| Zhu, DL | 1 |
| Eldawoody, H | 1 |
| Shimizu, H | 1 |
| Kimura, N | 1 |
| Saito, A | 1 |
| Nakayama, T | 1 |
| Takahashi, A | 1 |
| Tominaga, T | 1 |
| Deng, L | 1 |
| Li, G | 1 |
| Li, R | 1 |
| Liu, Q | 1 |
| He, Q | 1 |
| Zhang, J | 1 |
| Suzuki, H | 1 |
| Yamamoto, T | 1 |
| Fujigaki, Y | 1 |
| Eguchi, S | 1 |
| Hishida, A | 1 |
| Hou, SW | 1 |
| Liu, CY | 1 |
| Li, YH | 1 |
| Yu, JZ | 1 |
| Feng, L | 1 |
| Liu, YT | 1 |
| Guo, MF | 1 |
| Xie, Y | 1 |
| Meng, J | 1 |
| Zhang, HF | 1 |
| Xiao, BG | 1 |
| Ma, CG | 1 |
| Satoh, Si | 1 |
| Ikegaki, I | 1 |
| Toshima, Y | 1 |
| Watanabe, A | 1 |
| Asano, T | 1 |
| Shimokawa, H | 2 |
| Ying, H | 1 |
| Biroc, SL | 1 |
| Li, WW | 1 |
| Alicke, B | 1 |
| Xuan, JA | 1 |
| Pagila, R | 1 |
| Ohashi, Y | 1 |
| Okada, T | 1 |
| Kamata, Y | 1 |
| Dinter, H | 1 |
| Chapados, R | 1 |
| Abe, K | 1 |
| Ihida-Stansbury, K | 1 |
| McKean, D | 1 |
| Gates, AT | 1 |
| Kern, M | 1 |
| Merklinger, S | 1 |
| Elliott, J | 1 |
| Plant, A | 1 |
| Jones, PL | 1 |
| Oka, M | 1 |
| Homma, N | 1 |
| Taraseviciene-Stewart, L | 1 |
| Morris, KG | 1 |
| Kraskauskas, D | 1 |
| Burns, N | 1 |
| Voelkel, NF | 1 |
| McMurtry, IF | 1 |
| Kolavennu, V | 1 |
| Zeng, L | 1 |
| Peng, H | 1 |
| Danesh, FR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for fasudil and Disease Exacerbation
| Article | Year |
|---|---|
Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Progression; Humans; Molecular Targe | 2020 |
Rho GTPases in hepatocellular carcinoma.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Carcinoma, Hepatocellular; Disease P | 2009 |
17 other studies available for fasudil and Disease Exacerbation
| Article | Year |
|---|---|
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals | 2017 |
DES-ncRNA: A knowledgebase for exploring information about human micro and long noncoding RNAs based on literature-mining.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alzheimer Disease; Data Mining; Dictionaries as Topic | 2017 |
The influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Antigens, CD; Cadherins; Cell Line; Disease P | 2017 |
ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in Spinal Muscular Atrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Benzimidazoles; Cell Death; Cell Line; Cytop | 2017 |
Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Chemistry, Pharmaceutical; Disease Progressi | 2018 |
Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Albuminuria; Animals; Diabetes Mellitus, Type 2; Diab | 2013 |
Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amyotrophic Lateral Sclerosis; Animals; Disease Model | 2013 |
Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apolipoproteins E; Atherosclerosis; Blood Pr | 2009 |
Fasudil, a Rho-kinase inhibitor, attenuates induction and progression of cerebral aneurysms: experimental study in rats using vascular corrosion casts.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Cerebral Arteries; Disease Models, An | 2010 |
Rho-kinase inhibitor, fasudil, suppresses glioblastoma cell line progression in vitro and in vivo.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Blotting, Western; Cell Line, Tum | 2010 |
Comparison of ROCK and EGFR activation pathways in the progression of glomerular injuries in AngII-infused rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Disease Progression; ErbB Re | 2011 |
Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acid Sequence; Animals; Anti-Inflammatory Agent | 2012 |
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cardiomyopathies; Chronic Disease; Disease M | 2002 |
The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Breast Neoplasms; Cell Adhesion; Cell Growth | 2006 |
ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Blood Vessels; Cell Adhesion; Cell S | 2006 |
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Disease Progression; | 2007 |
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Collagen Type IV; Diabetic Ne | 2008 |